High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.
about
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsPharmacological treatments for non-alcohol related fatty liver disease (NAFLD): a network meta-analysisNon-alcoholic fatty liver disease: what the clinician needs to know.A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLDEndocrine causes of nonalcoholic fatty liver diseaseNonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment optionsThe role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic reviewNon-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatmentTreatment of nonalcoholic steatohepatitis in adults: present and futureNonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionineReview article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)Hepatic steatosis and Type 2 diabetes: current and future treatment considerations.Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseMolecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.Nonalcoholic fatty liver disease and cardiovascular diseasePre-and-post transplant considerations in patients with nonalcoholic fatty liver disease.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Review article: the management of paediatric nonalcoholic fatty liver disease.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseFocus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.Non-alcoholic fatty liver disease in 2015.Revision and update on clinical practice guideline for liver cirrhosis.NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trialBile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
P2860
Q22299426-B5CB7AC2-7B96-4959-A417-9E1935095BCDQ24186865-F80756D9-EF82-4D8D-BCD6-FDC2F72F21ABQ24563068-A963897D-01BC-4CEE-B356-FF57C887B7A2Q26752487-44AA6D61-92F3-4FA6-A3C3-5D4D3464DA43Q26780254-8AF5E01F-6A1E-4333-8969-7AE79E2315A1Q26796448-913B46BB-8213-43AB-852A-EF680B2C1C5EQ26825269-8DB42D7F-D9E5-498E-B72A-616E0588DD21Q26829503-6BD9AE29-4142-4934-BF8D-0BC1AF111715Q26852019-9D3ECDBA-1DD8-4999-8C89-706AF66649FBQ26852403-B0C6C500-E287-4F12-81F9-48CB0F2A7006Q26992163-2C67C867-9B2B-4EF3-A5E6-A2E1F566C5F2Q26998093-48EFFCDD-F975-414D-AF24-6B4419D787B4Q27007515-D6D86288-EEE9-443F-B223-BAC17D890C83Q27691399-3DD8C8CE-DEA4-4804-B6BF-27B2C99382E3Q30248535-0052510E-E825-4DDB-AF19-D7C42EC76B7AQ30389752-2C63B319-C829-4C1F-8BAB-E8F45FC5D9EEQ30401022-5CC6F5B1-FA76-442E-BB58-B4E1BB16286CQ30622511-2FEE4432-35BA-4F26-9245-6820FD500171Q33607697-5EBE2DB0-07B2-4ACF-A987-B0A4216E843DQ33755566-D0CFA33B-C646-469F-9875-2015ABBD26C3Q33855157-69756FC4-EABA-41F7-A0F8-DEC64B2DA529Q33886952-4F0DE4DF-8CAD-4B98-9E68-BDC6D6FF09D5Q33891750-736D3C87-04D3-4C2F-B669-E6BD904FFBD7Q34168532-03FB7E5B-E965-40C9-A1F6-4815341EC06AQ34440962-7D5C25BE-75D1-4152-BC3B-B0AEAF705102Q34449857-A1FEC6BF-3A34-4F68-BF22-57FC0D50F024Q34647400-05B1BE5C-85BB-4610-8ADA-4FF5BDBD7E19Q34760318-82B40265-A28C-4621-AFC9-B7A94BC91925Q35672242-0EEC60BD-0788-4229-8DB6-473BCFBEE2AEQ35715883-CECED309-C4B2-487E-87F6-B2B0E8912986Q35890613-A0A78CAF-3308-4CED-91E2-C09D2CC56E9EQ35931190-14CAD184-6C91-42B0-8A2F-FE1A3B2BF389Q36197335-812E5560-D455-4192-B150-CF9B7181E0FDQ36207195-DF09F6C8-9A17-4E04-9030-330B37718325Q36791363-A893BCDE-CE19-49EB-B3DA-DE988D0A2D58Q36981317-D3897C8F-2EB8-4FCC-BFFF-575A16394C14Q37101542-99832CB8-603A-4971-8D5F-AB220224FFC2Q37488800-70F6D3C9-1000-4853-96E5-719579E1B171Q37515585-51714CE0-4601-46D2-9BCE-1C068FD5C5A1Q37538343-F73CB499-186D-481E-AF9F-1EF71FAD1E68
P2860
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@en
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@nl
type
label
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@en
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@nl
prefLabel
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@en
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@nl
P2093
P2860
P356
P1433
P1476
High-dose ursodeoxycholic acid ...... zed, placebo-controlled trial.
@en
P2093
Birgit Lindenthal
Günter Herrmann
Hans-Jörg Cordes
Jasper Hein
Joachim C Arnold
Martin Rössle
NASH Study Group
Thomas Berg
Ulrich F H Leuschner
P2860
P304
P356
10.1002/HEP.23727
P407
P577
2010-08-01T00:00:00Z